



# Way2Drug

## cheminformatics platform for drug repurposing

Third International School-Seminar "From Empirical to Predictive chemistry"

Druzhilovskiy Dmitry

**Institute of Biomedical Chemistry**

119121, Moscow, Russia, Pogodinskaya street 10/8



Russian  
Science  
Foundation



विज्ञान एवं प्रौद्योगिकी विभाग  
DEPARTMENT OF  
**SCIENCE & TECHNOLOGY**

(RSF-DST No 16-45-02012-INT/RUS/RSF/12)



# Way2Drug available online

India    Russia    Ukraine    Mexico    China    United States    Egypt  
 Kazakhstan    Brazil    Other

Authorization/privacy

Free availability  
 24/7/365

22 users  
 2818 prediction

91 country



642 238 molecules

18 200 users

Users relationships

Cross-browser and cross-platform support





We have proposed the concept of local conformity from which activity of drug-like compounds is based on the recognition of the ligand atoms of the target atoms.

Using this concept, we have developed a consistent system of atom-centered neighborhoods of atoms descriptors including MNA, QNA, and LMNA, and have implemented them in several SAR/QSAR/QSPR modeling approaches. It's significant to note that all procedures on the basis of this portal use only structural formula for obtaining results.



# Way2Drug – Drug Repositioning

**Way2Drug** PREDICTIVE SERVICES  
Understanding Chemical-Biological Interactions

**Molecular Property Diagnostic Suite (MPDS™)**  
An Open Source Chemoinformatics Portal

A Knowledge Based Approach to Drug Repurposing for Socially Important and Rare Diseases.

RSF - DST Project # 16-45-02012 - INT/RUS/RSF/12

HOME

ABOUT

SERVICES

Hello, D Dr LOG OUT ~

LEISHMANIASIS



TUBERCULOSIS

DIABETES

EPILEPSY

CANCER

MALARIA



## Global research

Discovery of new safe and potent medicines based on cutting-edge knowledge of a certain pathology at the molecular, cellular, tissue and organism levels, and the most



## Referential ideas

Integration of the currently available biomedical and chemical data, extraction of the useful information and generation of new knowledge in the field of chemical-biological



## New services

Computational predictions based on perpetually updated information, which overcome the limits of the current knowledge and allow to expand predictive functionalities of



## Collaboration


Providing framework for effective interaction of researchers working in the multidisciplinary field of drug design & discovery, to combine their complementary background,



## Orphan diseases

A disease is considered rare\* when no more than **1 out of 2000** people suffer from it

Estimates indicate **>300 million** people living with a rare disease worldwide



Tests for **3500** rare diseases are now available...



...but only about **400 rare diseases** have therapies



**80%** of rare diseases have a genetic component

**50%** of those affected by rare diseases are children

Reported rates of medication adherence range from **58-65%**



There are **6,000 to 7,000** rare diseases

## MALARIA FACTS

Malaria is a serious disease that is **PREVENTABLE** and **TREATABLE**.

**97** countries and territories had ongoing malaria transmission in 2015.\*




a child dies from malaria in Sub-Saharan Africa.\*

## DIABETES

DIABETES IS ON THE RISE  
**422 MILLION** adults have diabetes

3.7 MILLION deaths due to diabetes and high blood glucose

1.5 MILLION deaths caused by diabetes



## Epilepsy

Epilepsy is a condition that affects the brain and causes repeated seizures



**65 MILLION** people worldwide currently live with epilepsy.

**200,000** people per year are diagnosed with epilepsy

## TUBERCULOSIS (TB) FACTS

TB is a serious disease. It can infect many body parts, but is most common in the lungs.



**9,000,000** people fell ill with TB

TB is a leading cause of death in patients with HIV.



**1,500,000** died from the disease\*

## Cancer Facts

approximately 14 million new cases



The disease accounts for 7.4 million deaths worldwide. It's the leading cause of death worldwide, causing around 13% of all deaths worldwide




Tuberculosis



Leishmaniasis



Malaria



Diabetes





Cancer



Epilepsy



# Way2Drug – Drug Repositioning



- development of computer methods for searching promising pharmacological targets and designing their ligands
- integration the developed methods into a common web platform
- validation using examples of searching for new drugs



# Pharmacological Targets

Show  entries

## Pharmacological Targets

Search:

Target's name	UniProt	PDB	Kegg	Pharmacotherapeutic application		
				PreClinical	Clinical	Launched
1-deoxy-D-xylulose 5-phosphate reductoisomerase	Q8IKG4				Tuberculosis	Malaria
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1	P19174				Cancer	
11beta-Hydroxysteroid Dehydrogenase (nonspecified subtype)	P24385					Diabetes Cancer
14-3-3 protein epsilon	P62258			Cancer		
15-hydroxyprostaglandin dehydrogenase (NAD+) (isoform 1)	P15428				Cancer	
17beta-Hydroxysteroid dehydrogenase (nonspecified subtype)	P24864				Cancer Diabetes	
2-amino-3-carboxymuconate-6-semialdehyde	Q8TDX5				Diabetes	
3-oxoacyl-(acyl-carrier protein) reductase	Q8I2S7				Cancer Leishmaniasis Malaria	
3-phosphoinositide-dependent protein kinase 1 (isoform 1)	O15530				Diabetes	Cancer
4F2 cell-surface antigen heavy chain	P08195			Cancer		
Target's name	UniProt	PDB	Kegg	Pharmacotherapeutic application		
				PreClinical	Clinical	Launched

Showing 1 to 10 of 2,322 entries



# Pharmacological Targets

UniProtKB

BLAST Align Retrieve/ID mapping Peptide search Help Contact

## UniProtKB - O00763 (ACACB\_HUMAN)

Display


Publications  
Feature viewer  
Feature table

RCSB PDB An Information Portal to 126809 Biological Macromolecular Structures

[Advanced Search](#) | [Browse by Annotations](#)

[PDB-101](#) [PDB](#) [EMDataBank](#) [StructuralBio](#) [Worldwide Protein Data Bank Association](#)

[f](#) [t](#) [v](#) [d](#) [y](#) [t](#) [u](#) [b](#) [e](#)



Similarity Structure Similarity Experiment

of RSGI RUH-053, an Apo-Biotin Carboxy Carrier Protein from Human

Released: 2006-10-25  
Ruhul Momen, A.Z.M., Hirota, H., Hayashi, F., Yokoyama, S., RIKEN Structural Initiative

Knowledgebase: 2DN8 (3 models >19 annotations) [SBKB.org](#)

Snapshot

Metric	Percentile Ranks	Value
Clashscore		14
Ramachandran outliers		1.7%
Sidechain outliers		25.0%

et Function Structures  
Structures with the Least





# FDA approved drugs (1035 drugs)

Show  entries Search:

Structure ↑↓	Generic Name ↑↓	Brand Name ↑↓	Mechanism of Action ↑↓	Pharmacotherapeutic application ↑↓	PASSOnline prediction ↑↓	FDA link ↑↓	Chembl link ↑↓																								
	Adenuric Febric Feburic Uloric	Febuxostat (USAN; Rec INN)	Xanthine oxidase inhibitor Xanthine dehydrogenase inhibitor(CHEMBL1929)	Gout Hyperuricemia Cancer therapy associated disorders Angina pectoris, stable Hematologic-blood cancer		101V0R1N2E	chembl1164729																								
	Lopurin Zylor (sodium salt)		Xanthine dehydrogenase inhibitor(CHEMBL1929)	Heart failure Urolithiasis Asphyxia neonatorum Nephropathy, diabetic Gout Hyperu		63CZ7GJN5I	chembl1467																								
	Edecrin Hydro		Wnt signaling inhibitor Sodium-(potassium)-chloride cotransporter 2 inhibitor(CHEMBL1874)	Hypert	PASS Online prediction for Febuxostat (USAN; Rec INN) <table border="1"> <thead> <tr> <th>Pa</th> <th>Pi</th> <th>Activity</th> </tr> </thead> <tbody> <tr> <td>0,936</td> <td>0,001</td> <td>Xanthine oxidase inhibitor</td> </tr> <tr> <td>0,878</td> <td>0,002</td> <td>Gout treatment</td> </tr> <tr> <td>0,821</td> <td>0,002</td> <td>Uric acid excretion stimulant</td> </tr> <tr> <td>0,631</td> <td>0,010</td> <td>Antidiabetic</td> </tr> <tr> <td>0,563</td> <td>0,008</td> <td>Mediator release inhibitor</td> </tr> <tr> <td>0,556</td> <td>0,005</td> <td>Lipoprotein disorders treatment</td> </tr> <tr> <td>0,636</td> <td>0,093</td> <td>Ubiquinol-cytochrome-c reductase inhibitor</td> </tr> </tbody> </table>			Pa	Pi	Activity	0,936	0,001	Xanthine oxidase inhibitor	0,878	0,002	Gout treatment	0,821	0,002	Uric acid excretion stimulant	0,631	0,010	Antidiabetic	0,563	0,008	Mediator release inhibitor	0,556	0,005	Lipoprotein disorders treatment	0,636	0,093	Ubiquinol-cytochrome-c reductase inhibitor
Pa	Pi	Activity																													
0,936	0,001	Xanthine oxidase inhibitor																													
0,878	0,002	Gout treatment																													
0,821	0,002	Uric acid excretion stimulant																													
0,631	0,010	Antidiabetic																													
0,563	0,008	Mediator release inhibitor																													
0,556	0,005	Lipoprotein disorders treatment																													
0,636	0,093	Ubiquinol-cytochrome-c reductase inhibitor																													
	Suxinutin Zar		Voltage-gated T-type calcium channel blocker(CHEMBL2362995)	Epileps																											

Close

**Cancer**  
(234 drugs)

**Malaria**  
(12 drugs)

**Tuberculosis**  
(20 drugs)

**Epilepsy**  
(41 drugs)

**Diabetes**  
(84 drugs)



# Similarity

## SimMNA | SimQNA

Show  entries

### Similarity MNA & QNA

Search:

Structure	Brand Name	Generic Name	Mechanism of Action	Pharmacotherapeutic application	Similarity MNA	Similarity QNA
	Asacard Aspirin Cardioaspirin Durlaza Ecotrin Nu-Seals Aspirin	Acetylsalicylic acid (BAN; USAN; JAN)	Cyclooxygenase inhibitor	Pain Stroke Polyposis coli, adenomatous Myocardial infarction Fever Hematologic Diseases Cognitive disorders Fatigue Thrombosis Ulcer, peptic Cancer, colorectal Angina pectoris, stable Cancer	1.000	1.000
	Zypadhera Zyprexa LAI Zyprexa Relprev	Olanzapine pamoate (USAN)	Dopamine D2 antagonist Signal transduction modulator 5 Hydroxytryptamine 2A antagonist	Schizophrenia	0.417	0.692
	Metopiron Metopirone	Metyrapone (BAN; USAN; Rec INN; JAN)		Cushing's syndrome	0.231	0.549








# Pharmaceutical Substances Registered in Russia

Show 10 entries

## Pharmaceutical Substances Registered in Russia

Search:

Structure	Trade name	Substance name	Comments
	Фосфаден	ADENOSINE PHOSPHATE	Торговое название: Фосфаден Международное название: Аденозина фосфат Страна: Россия . дата актуализации - 17.05.1999 (РЛС)
	Пентамин	AZA	Торговое название: Пентамин Международное название: Азаметония бромид Страна: Россия . В нескольких препаратах, несколько дат регистрации.
	Азатиоприн	AZA	Торговое название: Азатиоприн Международное название: Азатиоприн Страна: Россия
	СКИНОПЕН	AZELAIC ACID	мазь . Торговое название Скинорен (Skinoren) Страна-производитель Германия Фирма-производитель Schering AG - 10.11.1998 . . .






# Molecule Properties Prediction by Molecular Property Diagnostic Suite

- Prediction molecular properties;
- Heat Map of the MPDS predicted characteristics.

**Molecular Property Diagnostic Suite**

MPDS ID: 25-12-047870



**Molecular Formula:**  
C<sub>16</sub>H<sub>16</sub>ClNO<sub>2</sub>S

**IUPAC Name:**  
1-[2-(5-bromo-8-hydroxyquinolin-2-yl)ethyl]pyrrolidin-1-ium

**Remarks:**  
Remarks here...

**Name/Synonyms:**  
Name/Synonyms here...

**Molecular Properties:**

Mol. Wt.	321.06	LogP	0.94
HBD	0	LogS	-4.27
HBA	3	pKa	pKa1: ; pKa2: ; pKa3: 4.77; pKa4: -7.74
Molar refractivity	43.95	Polar surface area	57.78
Heavy atoms count	21	Rings count	3.00
Rotatable bonds	6.00	Polarizability	1.78

MPDS ID: 25-12-047881  
Molecular Formula: C<sub>16</sub>H<sub>13</sub>ClN<sub>3</sub>O<sub>2</sub>S  
IUPAC Name: trideuteriomethyl (2S)-2-(2-(chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate  
LogP=0.94  
LogS=-4.27  
HBA=3  
HBD=0  
pKa=pKa1: ; pKa2: ; pKa3: 4.77; pKa4: -7.74  
Molar refractivity=43.95  
Polar surface area=57.78  
Heavy atoms count=21  
Rings count=3.00  
Rotatable bonds=6.00  
Polarizability=1.78

Parameter	Value	Lipinski rule of five	Ghose Filters	CMC-like rules	MDDR like rule
LogP	0.94	●	●	●	
HBA	3	●			
HBD	0	●			
refract	43.95		●	●	
n_rotatable	6.00				●
n_rings	3.00				●
molwt	321.06	●	●	●	

MPDS website is hosted at Centre for Molecular Modelling  
CSIR-IICT, Hyderabad, India  
<http://mpds.osdd.net/>

<http://www.way2drug.com/dr>



# Molecular Property Diagnostic Suite

## MPDS<sup>DM</sup>

Galaxy / MPDS-DM
Analyze Data Workflow Shared Data Visualization Help User
Using 0 bytes

Tools

- MPDS 1.0.1
- Get Data
- DATA LIBRARIES
- Literature
- Target Library
- Gene Library
- Compound Library
- DATA PROCESSING
- Drug Repurposing Tool
- File-Format Converter
- Descriptor Calculation
- DATA ANALYSIS
- QSAR
- Docking
- Screening
- Visualization
- GALAXY INBUILT
- Graph/Display Data
- Workflows
  - All workflows

### Molecular Property Diagnostic Suite: (MPDS<sup>DM</sup>)

## An Open Source Diabetes Mellitus Portal

Hosted at Centre for Molecular Modeling, CSIR-ICT, Hyderabad  
<http://cmm.osdd.net/gnsmmg>

HOME
MPDS
CONTACT

Welcome to the Home of Molecular Property Diagnostic Suite (Diabetes Mellitus)

MPDS-DM consists of three modules. It covers informatics (Databases, File format conversion), structure and analogue based drug design approaches (property calculation, QSAR, Docking):

```

graph TD
    A[Diabetes Genes (NCBI) (1790)] --> B[Literature Screening (1145 Genes)]
    B --> C1[Type-1&2 (42)]
    B --> C2[Type-1 (T1D) (236)]
    B --> C3[Type-2 (T2D) (621)]
    B --> C4[Diabetes Related (246)]
    C2 --> C2_1[Targets (59)]
    C2 --> C2_2[Biomarkers (34)]
    C2 --> C2_3[Therapeutic agents (10)]
    C2 --> C2_4[Associated proteins (133)]
    C3 --> C3_1[Targets (149)]
    C3 --> C3_2[Biomarkers (62)]
    C3 --> C3_3[Therapeutic agents (9)]
    C3 --> C3_4[Associated proteins (401)]
          
```

History

Unnamed history  
(empty)

*This history is empty. You can load your own data or get data from an external source*



# Similarity FDA PCP Search

Show  entries

## FDA PCP Search

Search:

Structure ↑↓	Brand Name ↑↓	Generic Name ↑↓	Chembl ID ↑↓	mw ↑↓	logp ↑↓	HBA ↑↓	HBD ↑↓	TPSA ↑↓	nRB ↑↓	nAromRing ↑↓	nHB ↑↓	Similarity MNA ↓↑	Similarity QNA ↓↑
	Asacard Aspirin Cardioaspirin Durlaza Ecotrin Nu-Seals Aspirin	Acetylsalicylic acid (BAN; USAN; JAN)	25	171.98	2.021	3	0	43.37	3	1	3	1.000	1.000
	Disalcid Salflex	Salsalate (Prop INN; USAN; BAN)		247.97	3.811	3	0	43.37	4	2	3	0.633	0.449
	GranuPAS PASER Pamisyl Para-aminosalicylic acid Lucane Salf-Pas	4-Aminosalicylic acid para-Aminosalicylic acid	1169	145.99	0.469	3	0	17.07	1	1	3	0.417	0.315
	Epatec Fastum Ibifen Impracor Keplat Ketocid Ketoselect	Ketoprofen (BAN; USAN; Rec INN; JAN)	571	239.98	4.988	3	0	34.14	4	2	3	0.417	0.437



# PASS Total: selection of prediction features

Draw a structure:

To receive results, please, enter:

Choose activities/properties which you want to predict:

- Select/unselect all
- PASS Online(all activities)
- PASS Online (Effects)
- PASS Online(Mechanism)
- PASS Online(Metabolism)
- PASS Online(Transport)
- PASS Online (Adverse\_Effects&Toxicity)
- SOMP (Site of metabolism prediction)
- GUSAR (Antitarget)
- GUSAR (Acute Rat Toxicity)
- GUSAR (Enviromental Toxicity)
- DIGEP-Pred (mRNA Level)
- DIGEP-Pred (Protein Level)
- BBB

And finally:

[Click here to predict](#)

# PASS Total: main prediction tools







PAS

- Antidiabetic
- Antidiabetic (type 1)
- Antidiabetic (type 2)
- Antidiabetic symptomatic
- Antituberculosic
- Kegg link
- all activity

● Pa>Pi ○ Pa>0,3 ○ Pa>0,7



0,847	0,005	Superoxide dismutase inhibitor
0,783	0,004	Transketolase inhibitor
0,646	0,008	Erythropoiesis stimulant
0,575	0,014	APOA1 expression enhancer
0,576	0,033	Calcium channel (voltage-sensitive) activator
0,519	0,014	Caspase 8 stimulant
0,496	0,006	TRPA1 agonist
0,486	0,007	Monophenol monooxygenase inhibitor
0,453	0,036	Caspase 3 stimulant
0,412	0,006	Alcohol dehydrogenase inhibitor
0,361	0,019	Dihydroorotase inhibitor
0,337	0,007	Glutamine-tRNA ligase inhibitor
0,395	0,066	Fibroblast growth factor agonist
0,368	0,047	CF transmembrane conductance regulator

Homo sapiens(P00441)


Click to Unirpot

- Peroxisome
- Amyotrophic lateral sclerosis (ALS)
- Huntington's disease
- Prion diseases


Click to view kegg db



Mus musculus



Rattus norvegicus



Homo sapiens

**Antidiabetic**  
**Antidiabetic (type I)**  
**Antidiabetic (type II)**  
**Antidiabetic symptomatic**  
**Antituberculosic**



## SAR Creator


ADD STRUCTURE

VIEW STRUCTURES

VIEW/CREATE SDF FILES

I NEED HELP

### Structure



SMILES

CC(=O)Oc1ccccc1C(=O)O

CHEMBL ID

CHEMBL25

INCHI Key

BSYNRYMUTXBXSQ-UHFFFAOYSA-N

Structure

Compound's name

Activity

Group

Save



# Summary:

- database includes approved drugs registered by U.S. Food and Drug Administration;
- database includes more than 1400 substances of medicines registered in the Russian Federation;
- knowledge base includes pharmacological targets, the impact on which is used/studied for the treatment of cancer, diabetes, tuberculosis, etc ..;
- hypertext links between more than 1200 pharmacological targets, the impact on which is predicted by the PASS Online program, with the UniProt, KEGG, PDB databases;
- assessing new therapeutic potential of known medicines using heat map of the MPDS predicted characteristics ;
- SAR Creator software allows you to create online training sets for (Q) SAR models;
- the web services provide a prediction of interactions with ~ 80% of molecular targets that are studied in the target pharmacotherapeutic area.

## Acknowledgements

### IBMC, Moscow, Russia

Vladimir Poroikov, Prof.

Anastassia Rudik, Ph.D.

Dmitry Filimonov, Ph.D.

Alexey Lagunin, Dr. Sci.

Tatyana Glorizova, M.Sc.

Pavel Pogodin, M.Sc.

Khalimat Murtazalieva, Student

Vladislav Bezhentsev, Student

Daria Veselova, Student

Polina Savosina, Student

### CDIR-IICT, Hyderabad, India

Narahari Sastry, Prof, Ph.D.

Karunakar Tanneeru, Ph.D.

Anamika Singh Gaur

R. Srinithi



For providing IBMC academic license on Integrity.



Russian  
Science  
Foundation



विज्ञान एवं प्रौद्योगिकी विभाग  
DEPARTMENT OF  
**SCIENCE & TECHNOLOGY**

सत्यमेव जयते

Supported by the Russian Science Foundation and Indian Department of Science and Technology grants No. 16-45-02012 - INT/RUS/RSF/12 “A Knowledge Based Approach to Drug Repurposing for Socially Important and Rare Diseases”